Cancer cell lines with amplification of MET (HCT116), activating mutations in RAS family members (HCT116, SW480, NCI-H460, NCI-H23 and A549) and PI3K subunits (HCT116, DU145, MDA-MB-435, NCI-H460 and NCI-H2170) were all responsive to LXY18, indicating that these cancer drivers do not correlate absolutely with resistance to LXY18. The gene discussed is MET; the disease is cancer.